The First Drug-Repeatable Gene Therapy—Beremagene Geperpavec (B-VEC)—Approved by FDA
The FDA approved Beremagene Geperpavec (B-VEC), also known by its trade name Vyjuvke, on May 19, 2023, for the treatment of dystrophic maculopapularity in patients aged 6 months and older with epidermolysisRead More…